Stocktoria
NextCure, Inc. NXTC
NextCure, Inc. financials (annual)
Bars are annual figures from 2018 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $22.4M | $6.3M | — |
| R&D expense | $44.9M | $41.5M | $47.9M | $54.2M | $50.2M | $46.6M | $34.2M | $19.8M |
| Operating income | -$57.6M | -$59.7M | -$67.6M | -$75.9M | -$70.8M | -$41.2M | -$37.5M | -$23.2M |
| Interest expense | — | — | — | — | — | $183,000 | $209,000 | $25,000 |
| Income tax | $0 | — | — | — | — | — | — | — |
| Net income | -$55.8M | -$55.7M | -$62.7M | -$74.7M | -$69.4M | -$36.6M | -$33.7M | -$22.8M |
| EPS (diluted) | $-19.65 | $-23.88 | $-2.25 | $-2.69 | $-2.51 | $-1.33 | — | — |
| Operating cash flow | -$49.6M | -$40.8M | -$53.0M | -$53.9M | -$57.3M | -$45.0M | -$35.6M | $8.0M |
| Free cash flow | — | -$41.3M | -$53.8M | -$56.0M | -$59.6M | -$52.1M | -$39.0M | $4.9M |
| Cash & equivalents | $26.0M | $27.7M | $13.1M | $26.6M | $12.3M | $32.8M | $34.1M | $135.2M |
| Total assets | $50.2M | $80.9M | $128.0M | $184.2M | $242.4M | $306.6M | $356.2M | $147.6M |
| Total liabilities | $15.2M | $15.4M | $13.6M | $16.6M | $9.0M | $12.9M | $34.7M | $32.3M |
| Shareholders' equity | $34.9M | $65.5M | $114.4M | $167.5M | $233.4M | $293.7M | $321.5M | -$46.9M |
Growth · year-over-year · Revenue CAGR 252.6%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue growth | — | — | — | — | — | +252.6% | — | — |
| Free cash flow growth | — | — | — | — | — | — | -891.1% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.